Sonoma Pharmaceuticals, Inc. (SNOA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Sonoma Pharmaceuticals, Inc. on September 26, 2025. The filing reports the entry into a material definitive agreement to facilitate the sale of the company's common stock.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or debt metrics. The only financial figure disclosed relates to the potential capital raise:
- Maximum Offering Amount: Up to $2,070,463 in aggregate gross proceeds.
- Commission Fee: 3% of aggregate gross proceeds payable to the agent.
- Expense Reimbursement: Up to $40,000 for specified expenses.
Material Changes
On September 26, 2025, the Company entered into an At Market Issuance Sales Agreement with Ladenburg Thalmann & Co. Inc. ("Ladenburg"). Key terms include:
- Agent Role: Ladenburg will act as the agent to sell shares of common stock ($0.0001 par value) from time to time based on the Company's instructions.
- Sale Method: Sales may be conducted via "at the market" offerings under Rule 415 or other permitted methods, including privately negotiated transactions.
- Registration: Sales are made pursuant to an effective Form S-3 registration statement (File No. 333-275311) and a prospectus supplement filed on September 26, 2025.
- Termination: The agreement terminates upon the sale of all shares or as otherwise provided in the agreement.
Guidance, Outlook, and Risks
Outlook and Obligations: The Company is not obligated to make any sales under the agreement. No assurance is given that any shares will be sold, nor regarding the price, amount, or timing of potential sales.
Risks and Forward-Looking Statements: The filing includes standard forward-looking statements regarding intentions and expectations. Actual results may differ materially due to risks discussed in the Company's Form 10-K. The report explicitly states it does not constitute an offer to sell or a solicitation of an offer to buy shares in any state where such offer would be unlawful.
Investor Verification Checklist
- Verify the current market price of SNOA to assess potential dilution impact from the $2,070,463 offering cap.
- Review the full text of the At Market Issuance Sales Agreement (Exhibit 1.1) for specific termination rights and conditions.
- Check the Company's most recent Form 10-K or 10-Q for current cash position and liquidity needs driving this financing.
- Confirm the status of the Form S-3 registration statement (File No. 333-275311) on the SEC EDGAR database.